Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Scott

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
BMC Rheumatology|March 20, 2019
Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritisNicola J Gullick, Fowzia Ibrahim, Ian C Scott, et al.
The Journal of Rheumatology|December 7, 2005
The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritisMark J Harrison, Karen J Tricker, Linda Davies, et al.
Rheumatology (Oxford, England)|October 3, 2017
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?Fowzia Ibrahim, Beatriz Lorente-Cánovas, Caroline J Doré, et al.
The Journal of Rheumatology|January 17, 2012
Remission in early rheumatoid arthritis: predicting treatment responseMargaret H Y Ma, Fowzia Ibrahim, David Walker, et al.
BMJ (Clinical Research Ed.)|March 15, 2015
Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trialDavid L Scott, Fowzia Ibrahim, Vern Farewell, et al.
Seminars in Arthritis and Rheumatism|June 14, 2014
Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohortsSam Norton, Bo Fu, David L Scott, et al.
Arthritis and Rheumatism|May 2, 2007
Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trialYuen-Li Chung, Helene Alexanderson, Nicoló Pipitone, et al.
The Journal of Rheumatology|February 17, 2017
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate MethotrexateMatt D Stevenson, Allan J Wailoo, Jonathan C Tosh, et al.
The Journal of Biological Chemistry|August 9, 2005
Huntingtin associates with acidic phospholipids at the plasma membraneKimberly B Kegel, Ellen Sapp, Jennifer Yoder, et al.
Rheumatology (Oxford, England)|November 30, 2014
Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroidsFowzia Ibrahim, Ernest Choy, Patrick Gordon, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
BMC Rheumatology|March 20, 2019
Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritisNicola J Gullick, Fowzia Ibrahim, Ian C Scott, et al.
The Journal of Rheumatology|December 7, 2005
The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritisMark J Harrison, Karen J Tricker, Linda Davies, et al.
Rheumatology (Oxford, England)|October 3, 2017
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?Fowzia Ibrahim, Beatriz Lorente-Cánovas, Caroline J Doré, et al.
The Journal of Rheumatology|January 17, 2012
Remission in early rheumatoid arthritis: predicting treatment responseMargaret H Y Ma, Fowzia Ibrahim, David Walker, et al.
BMJ (Clinical Research Ed.)|March 15, 2015
Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trialDavid L Scott, Fowzia Ibrahim, Vern Farewell, et al.
Seminars in Arthritis and Rheumatism|June 14, 2014
Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohortsSam Norton, Bo Fu, David L Scott, et al.
Arthritis and Rheumatism|May 2, 2007
Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trialYuen-Li Chung, Helene Alexanderson, Nicoló Pipitone, et al.
The Journal of Rheumatology|February 17, 2017
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate MethotrexateMatt D Stevenson, Allan J Wailoo, Jonathan C Tosh, et al.
The Journal of Biological Chemistry|August 9, 2005
Huntingtin associates with acidic phospholipids at the plasma membraneKimberly B Kegel, Ellen Sapp, Jennifer Yoder, et al.
Rheumatology (Oxford, England)|November 30, 2014
Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroidsFowzia Ibrahim, Ernest Choy, Patrick Gordon, et al.
Pageof 14